Alexander Semaan
Overview
Explore the profile of Alexander Semaan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Praktiknjo M, Pena Solano A, Sadeghlar F, Welchowski T, Schmid M, Mohring C, et al.
Sci Rep
. 2024 Sep;
14(1):22146.
PMID: 39333610
Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with...
2.
Woestemeier A, Semaan A, Kalff J, Lingohr P
Schmerz
. 2023 Nov;
38(1):6-11.
PMID: 37989790
The rare Dunbar syndrome or medial arcuate ligament syndrome (MALS) is defined as compression of the celiac trunk and/or ganglion by the medial arcuate ligament. It is often diagnosed after...
3.
Woestemeier A, Semaan A, Block A, Arensmeyer J, Dohmen J, Kania A, et al.
Orphanet J Rare Dis
. 2023 Oct;
18(1):334.
PMID: 37872625
Background: The median arcuate ligament syndrome (MALS) is a rare disease caused by compression of the celiac artery (ORPHA: 293208). Surgical treatment of MALS aims to restore normal celiac blood...
4.
Semaan A, Bernard V, Wong J, Makino Y, Swartzlander D, Rajapakshe K, et al.
Cancer Res Commun
. 2023 Sep;
3(10):2062-2073.
PMID: 37721516
Significance: Integrated molecular analysis of genomic and transcriptomic alterations in the multistep progression of IPMNs, which are bona fide precursors of pancreatic cancer, identifies features associated with progression of low-risk...
5.
Fischer A, Semaan A, Wulf A, Vokuhl C, Goltz D, Fischer H
Int J Hepatol
. 2023 Aug;
2023:4313504.
PMID: 37593089
Background: The promoter mutation represents a common and early event in hepatocarcinogenesis, but its linkage to the morphological status of the underlying liver tissue is poorly understood. We analyzed the...
6.
Kolbinger F, Bernard V, Lee J, Stephens B, Branchi V, Raghav K, et al.
J Gastrointest Cancer
. 2023 Mar;
54(4):1276-1285.
PMID: 36862364
Purpose: Cancer of unknown primary (CUP) accounts for 2-5% of all cancer diagnoses, wherein standard investigations fail to reveal the original tumor site. Basket trials allocate targeted therapeutics based on...
7.
Kramer B, Nalin A, Ma F, Eickhoff S, Lutz P, Leonardelli S, et al.
Cell Rep
. 2023 Jan;
42(1):111937.
PMID: 36640314
Group 1 innate lymphoid cells (ILCs) comprise a heterogeneous family of cytotoxic natural killer (NK) cells and ILC1s. We identify a population of "liver-type" ILC1s with transcriptional, phenotypic, and functional...
8.
Henn J, Wyzlic P, Esposito I, Semaan A, Branchi V, Klinger C, et al.
Langenbecks Arch Surg
. 2023 Jan;
408(1):28.
PMID: 36640188
Purpose: The detection of pancreatic cystic lesions (PCL) causes uncertainty for physicians and patients, and international guidelines are based on low evidence. The extent and perioperative risk of resections of...
9.
van Beekum C, Beckmann C, Semaan A, Manekeller S, Matthaei H, Braun L, et al.
Front Med (Lausanne)
. 2022 Jul;
9:886566.
PMID: 35814748
Background: Despite various existing scores that predict morbidity and mortality of patients with cirrhotic liver disease (CLD), data on specific risk stratification of patients with CLD undergoing colorectal surgery (CRS)...
10.
Monberg M, Geiger H, Lee J, Sharma R, Semaan A, Bernard V, et al.
Nat Commun
. 2022 Jun;
13(1):3652.
PMID: 35752636
Heterogeneity is a hallmark of cancer. The advent of single-cell technologies has helped uncover heterogeneity in a high-throughput manner in different cancers across varied contexts. Here we apply single-cell sequencing...